myriad genet market lead specialti
product analyz gene mutat assess
individu lifetim risk develop cancer risk
recurrence/diseas progress respons
particular treatment optim dose reduc
toxicity/high efficaci market product
intern sale forc call oncologist
ob/gyn
reason report
estim chang analysi sales/earn
guidanc fda statement pharmacogenom
test understand investor frustrat hiccup
volatil along way believ patienc reward
increment reimburs either genesight mypath
integr counsyl dramat inflect alreadi improv
mil expens potenti addit improv
adj ep still expect rang
import disclosur analyst certif page report access current disclosur stephen
inc cover compani client may refer
new product show double-digit growth rate futur growth support new companion diagnost
increment reimburs vectra prolari endopredict mypath melanoma product would
sent technic assess payor organ associ commerci live technic
bracanalysiscdxreceivedfdaapprovalasacompaniondiagnosticforpf sparpinhibitor talzenna
thousand except share data
good sold
research develop
less net loss attribut non-control interest
oper net incom loss attribut inc stockhold
research develop
bad debt expens revenu
research develop
compani report stephen inc estim
thousand except asp number
number test counsyl perform
market penetr market get test
percent total revenu
number test counsyl perform
market penetr market get test
percent total revenu
number test
percent total revenu
total counsyl contribut model
number test
percent total revenu
percent total revenu
number test
percent total revenu
number test
percent total revenu
percent total revenu
pharmaceut clinic servic revenu
pharmaceut clinic servic revenu
percent total revenu
compani report stephen inc estim
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
